Diabetes mellitus is a global health problem, and its prevalence continues to increase. Dietary supplements, including probiotics, prebiotics, and plant extracts, have been shown to alleviate diabetes. In this study, the synergistic effects of two types of dietary supplements were investigated in a mouse model of type 2 diabetes mellitus (T2DM). Sixty mice were divided into the following six groups: control, model (induced by a high-fat diet and intraperitoneal injection of streptozotocin), drug (metformin), probiotic (Lactobacillus spp.), formula A (probiotics, plant extracts, and soybean peptide), and formula B (probiotics, prebiotics, and soybean peptide). All three dietary interventions (probiotic, formula A, and formula B groups) significantly reduced the blood glucose level and oral glucose tolerance level and effectively improved some biochemical parameters (e.g., chronic inflammation, oxidative stress, and blood lipid level) and regulated gut microbiota. Notably, formula B exhibited a better ability on reducing the blood glucose level, regulating the gut microbiota, and increasing the short-chain fatty acid levels compared with the probiotics alone and formula A. Thus, formula B may exert synergistic protective effects against T2DM through a mechanism involving probiotics and prebiotics of gut microbiota regulation. This study provides a theoretical basis for the application of probiotic dietary supplements to the treatment of T2DM.
Get full access to this article
View all access options for this article.
References
1.
NeuenschwanderM, BallonA, WeberKS, et al.: Role of diet in type 2 diabetes incidence: Umbrella review of meta-analyses of prospective observational studies. BMJ, 2019; 366:l2368.
GilbertER, FuZ, LiuD: Development of a nongenetic mouse model of type 2 diabetes. Exp Diabetes Res, 2014; 2011:416254.
4.
RemelyM, HippeB, ZannerJ, AumuellerE, BrathH, HaslbergerAG: Gut microbiota of obese, type 2 diabetic individuals is enriched in Faecalibacterium prausnitzii, Akkermansia muciniphila and Peptostreptococcus anaerobius after weight loss. Endocr Metab Immune, 2016; 16:99–106.
5.
DevindraS, SudhishS, Shiv TejS: Sulfonylureas: Do we need to introspect safety again?. Expert Opin Drug Saf, 2011; 10:851–861.
6.
MarazzaJA, LeBlancJG, de GioriGS, GarroMS: Soymilk fermented with Lactobacillus rhamnosus CRL981 ameliorates hyperglycemia, lipid profiles and increases antioxidant enzyme activities in diabetic mice. J Funct Foods, 2013; 5:1848–1853.
7.
ZhengJ, YuanX, ChengG, et al.: Chitosan oligosaccharides improve the disturbance in glucose metabolism and reverse the dysbiosis of gut microbiota in diabetic mice. Carbohyd Polym, 2018; 190:77–86.
8.
KimKT, RiouxLE, TurgeonSL: Molecular weight and sulfate content modulate the inhibition of α-amylase by fucoidan relevant for type 2 diabetes management. Pharmanutrition, 2015; 3:108–114.
9.
LinHTV, TsouYC, ChenYT, LuWJ, HwangPA: Effects of low-molecular-weight fucoidan and high stability fucoxanthin on glucose homeostasis, lipid metabolism, and liver function in a mouse model of type II diabetes. Mar Drugs, 2017; 15:113.
10.
ShangQ, SongG, ZhangM, et al.: Dietary fucoidan improves metabolic syndrome in association with increased Akkermansia population in the gut microbiota of high-fat diet-fed mice. J Funct Foods, 2017; 28:138–146.
RahmanI, BiswasSK, KirkhamPA: Regulation of inflammation and redox signaling by dietary polyphenols. Biochem Pharmacol, 2006; 72:1439–1452.
13.
WuCT, ChiuCY, HuangCF, PengFC, LiuSH: Genotoxicity and 28-day oral toxicity studies of a functional food mixture containing maltodextrin, white kidney bean extract, mulberry leaf extract, and niacin-bound chromium complex. Regul Toxicol Pharm, 2018; 92:67–74.
14.
SpadafrancaA, RinelliS, RivaA, et al.: Phaseolus vulgaris extract affects glycometabolic and appetite control in healthy human subjects. Brit J Nutr, 2013; 109:1789–1795.
15.
KimGN, KwonYI, JangHD: Mulberry leaf extract reduces postprandial hyperglycemia with few side effects by inhibiting [alpha]-glucosidase in normal rats. J Med Food, 2011; 14:712–717.
16.
LuJ, ZengY, HouW, et al.: The soybean peptide aglycin regulates glucose homeostasis in type 2 diabetic mice via IR/IRS1 pathway. J Nutr Biochem, 2012; 23:1449–1457.
17.
LiX, WangN, YinB, et al.: Lactobacillus plantarum X1 with α-glucosidase inhibitory activity ameliorates type 2 diabetes in mice. RSC Adv, 2016; 6:63536–63547.
18.
ChenP, ZhangQ, DangH, et al.: Oral administration of Lactobacillus rhamnosus CCFM0528 improves glucose tolerance and cytokine secretion in high-fat-fed, streptozotocin-induced type 2 diabetic mice. J Funct Foods, 2014; 10:318–326.
19.
WangG, SiQ, YangS, et al.: Lactic acid bacteria reduce diabetes symptoms in mice by alleviating gut microbiota dysbiosis and inflammation in different manners. Food Funct, 2020; 11:5898–5914.
20.
MicheliL, LucariniE, TralloriE, et al.: Phaseolus vulgaris L. extract: Alpha-amylase inhibition against metabolic syndrome in mice. Nutrients, 2019; 11:1778.
MiyaharaC, MiyazawaM, SatohS, SakaiA, MizusakiS: Inhibitory effects of mulberry leaf extract on postprandial hyperglycemia in normal rats. J Nutr Sci Vitaminol (Tokyo), 2004; 50:161–164.
23.
ZhengJ, ChengG, LiQ, et al.: Chitin oligosaccharide modulates gut microbiota and attenuates high-fat-diet-induced metabolic syndrome in mice. Mar Drugs, 2018; 16:66.
24.
KumarSG, RahmanMA, LeeSH, HwangHS, KimHA, YunJW: Plasma proteome analysis for anti-obesity and anti-diabetic potentials of chitosan oligosaccharides in ob/ob mice. Proteomics, 2009; 9:2149–2162.
25.
LinHV, TsouYC, ChenYT, LuWJ, HwangPA: Effects of low-molecular-weight fucoidan and high stability fucoxanthin on glucose homeostasis, lipid Metabolism, and liver function in a mouse model of type II diabetes. Mar Drugs, 2017; 15:113.
26.
WangJ, LiuH, LiN, ZhangQ, ZhangH: The protective effect of fucoidan in rats with streptozotocin-induced diabetic nephropathy. Mar Drugs, 2014; 12:3292–3306.
27.
YuL, QiaoN, LiT, et al.: Dietary supplementation with probiotics regulates gut microbiota structure and function in Nile tilapia exposed to aluminum. Peer J, 2019; 7:e6963.
28.
ChamberlainJJ, JohnsonEL, LealS, RhinehartAS, PetersonL: Cardiovascular disease and risk management: Review of the American Diabetes Association Standards of Medical Care in Diabetes 2018. Ann Intern Med, 2018; 168:640–650.
29.
MartelJ, OjciusDM, ChangCJ, et al.: Anti-obesogenic and antidiabetic effects of plants and mushrooms. Nat Rev Endocrinol, 2017; 13:149–160.
30.
PasupathiP, ChandrasekarV, KumarUS: Evaluation of oxidative stress, enzymatic and non-enzymatic antioxidants and metabolic thyroid hormone status in patients with diabetes mellitus. Diabet Metab Synd Clin Res Rev, 2009; 3:160–165.
31.
SakaiT, TakiT, NakamotoA, et al.: Lactobacillus plantarum OLL2712 regulates glucose metabolism in C57BL/6 mice fed a high-fat diet. J Nutr Sci Vitaminol, 2013; 59:144–147.
32.
SircanaA, FramarinL, LeoneN, et al.: Altered gut microbiota in type 2 diabetes: Just a coincidence?. Curr Diab Rep, 2018; 18:98.
33.
HsiehFC, LeeCL, ChaiCY, ChenWT, LuYC, WuCS: Oral administration of Lactobacillus reuteri GMNL-263 improves insulin resistance and ameliorates hepatic steatosis in high fructose-fed rats. Nutr Metab, 2013; 10:35.
34.
LeeHW, ParkYS, ChoiJW, YiSY, ShinWS: Antidiabetic effects of chitosan oligosaccharides in neonatal streptozotocin-induced noninsulin-dependent diabetes mellitus in rats. Biol Pharm Bull, 2003; 26:1100–1103.
35.
QinJ, LiY, CaiZ, et al.: A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature, 2012; 490:55–60.
36.
WeiY, GongJ, ZhuW, et al.: Fecal microbiota transplantation restores dysbiosis in patients with methicillin resistant Staphylococcus aureus enterocolitis. BMC Infect Dis, 2015; 15:265.
37.
MartinR, LavalL, ChainF, et al.: Bifidobacterium animalis ssp. lactis CNCM-I2494 restores gut barrier permeability in chronically low-grade inflamed mice. Front Microbiol, 2016; 7:608.
38.
PanM, WanC, XieQ, et al.: Changes in gastric microbiota induced by Helicobacter pylori infection and preventive effects of Lactobacillus plantarum ZDY 2013 against such infection. J Dairy Sci, 2016; 99:970–981.
39.
XueM, JiX, LiangH, et al.: The effect of fucoidan on intestinal flora and intestinal barrier function in rats with breast cancer. Food Funct, 2018; 9:1214–1223.
40.
JangiS, GandhiR, CoxLM, et al.: Alterations of the human gut microbiome in multiple sclerosis. Nat Commun, 2016; 7:12015.
41.
GaoZY, YinJ, ZhangJ, et al.: Butyrate improves insulin sensitivity and increases energy expenditure in mice. Diabetes, 2009; 58:1509–1517.
42.
DevadderF, Kovatcheva-DatcharyP, GoncalvesD, et al.: Microbiota-generated metabolites promote metabolic benefits via gut-brain neural circuits. Cell, 2014; 156:84–96.
43.
KimYA, KeoghJB, CliftonPM: Probiotics, prebiotics, synbiotics and insulin sensitivity. Nutr Res Rev, 2018; 31:35–51.
44.
ZhuKX, NieS-P, TanL-E, LiC, GongD-M, XieM-Y: A polysaccharide from Ganoderma atrum improves liver function in type 2 diabetic rats via antioxidant action and short-chain fatty acids excretion. J Agr Food Chem, 2016; 64:1938.
45.
Neel JayeshShah, SwamiOC: Role of probiotics in diabetes: A review of their rationale and efficacy. EMJ Diabet, 2017; 5:104–110.
46.
WangYM, DilidaxiD, WuYC, SailikeJ, SunX, NabiXH: Composite probiotics alleviate type 2 diabetes by regulating intestinal microbiota and inducing GLP-1 secretion in db/db mice. Biomed Pharmacother, 2020; 125:109914.
47.
AndreasenAS, LarsenN, Pedersen-SkovsgaardT, et al.: Effects of Lactobacillus acidophilus NCFM on insulin sensitivity and the systemic inflammatory response in human subjects. Brit J Nutr, 2010; 104:1831–1838.
48.
NikbakhtE, KhalesiS, SinghI, WilliamsLT, WestNP, ColsonN: Effect of probiotics and synbiotics on blood glucose: A systematic review and meta-analysis of controlled trials. Eur J Nutr, 2018; 57:95–106.
49.
JiYY, KimSS: Probiotics and prebiotics: Present status and future perspectives on metabolic disorders. Nutrients, 2016; 8:173.
50.
Lenoir-WijnkoopI, SandersME, CabanaMD, et al.: Probiotic and prebiotic influence beyond the intestinal tract. Nutr Rev, 2010; 65:469–489.
51.
ShakeriH, HadaeghH, AbediF, et al.: Consumption of synbiotic bread decreases triacylglycerol and VLDL levels while increasing HDL levels in serum from patients with type-2 diabetes. Lipids, 2014; 49:695–701.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
